To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

DNA Methylation Screening… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

DNA Methylation Screening of Primary Prostate Tumors Identifies SRD5A2 and CYP11A1 as Candidate Markers for Assessing Risk of Biochemical Recurrence

Journal article
Authors A. M. Horning
Julius Adebayo Awe
C. M. Wang
J. Liu
Z. Lai
V. Y. Wang
R. R. Jadhav
A. D. Louie
C. L. Lin
T. Kroczak
Y. D. Chen
V. X. Jin
S. L. Abboud-Werner
R. J. Leach
J. Hernandez
I. M. Thompson
J. Saranchuk
D. Drachenberg
C. L. Chen
S. Mai
T. H. M. Huang
Published in Prostate
Volume 75
Issue 15
Pages 1790-1801
ISSN 0270-4137
Publication year 2015
Published at Institute of Biomedicine, Department of Medical and Clinical Genetics
Pages 1790-1801
Language en
Links dx.doi.org/10.1002/pros.23052
Keywords prostate cancer, DNA methylation, plasma, biochemical recurrence, GENE-EXPRESSION, RADICAL PROSTATECTOMY, CANCER PROGRESSION, CIRCULATING, DNA, ANTIGEN, PLASMA, GROWTH, SERUM, TESTOSTERONE, FINASTERIDE, Endocrinology & Metabolism, Urology & Nephrology, ATES OF AMERICA, V108, P13728
Subject categories Endocrinology, Urology and andrology

Abstract

BACKGROUND. Altered DNA methylation in CpG islands of gene promoters has been implicated in prostate cancer (PCa) progression and can be used to predict disease outcome. In this study, we determine whether methylation changes of androgen biosynthesis pathway (ABP)-related genes in patients' plasma cell-free DNA (cfDNA) can serve as prognostic markers for biochemical recurrence (BCR). METHODS. Methyl-binding domain capture sequencing (MBDCap-seq) was used to identify differentially methylated regions (DMRs) in primary tumors of patients who subsequently developed BCR or not, respectively. Methylation pyrosequencing of candidate loci was validated in cfDNA samples of 86 PCa patients taken at and/or post-radical prostatectomy (RP) using univariate and multivariate prediction analyses. RESULTS. Putative DMRs in 13 of 30 ABP-related genes were found between tumors of BCR (n = 12) versus no evidence of disease (NED) (n = 15). In silico analysis of The Cancer Genome Atlas data confirmed increased DNA methylation of two loci-SRD5A2 and CYP11A1, which also correlated with their decreased expression, in tumors with subsequent BCR development. Their aberrant cfDNA methylation was also associated with detectable levels of PSA taken after patients' post-RP. Multivariate analysis of the change in cfDNA methylation at all of CpG sites measured along with patient's treatment history predicted if a patient will develop BCR with 77.5% overall accuracy. CONCLUSIONS. Overall, increased DNA methylation of SRD5A2 and CYP11A1 related to androgen biosynthesis functions may play a role in BCR after patients' RP. The correlation between aberrant cfDNA methylation and detectable PSA in post-RP further suggests their utility as predictive markers for PCa recurrence. (C) 2015 Wiley Periodicals, Inc.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?